Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: 2

EUROASPIRE-IV: European Society of Cardiology study of lifestyle, risk factors, and treatment approaches in patients with coronary artery disease: Data from Turkey

EUROASPIRE-IV: Avrupa Kardiyoloji Derneği’nin koroner arter hastalarında yaşam tarzı, risk faktörleri ve tedavi yaklaşımı üzerine çalışması: Türkiye verileri

Pages
134–144
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: EUROASPIRE-IV Turkey data revealed that secondary prevention was unsatisfactory and had progressed unfavorably compared with last EUROASPIRE study, some risk factors were more uncontrolled than overall European average, and coronary artery events at young age remain an important problem.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Data from EUROASPIRE-IV Turkey report investigating risk factors and adherence to guidelines in patients hospitalized for coronary artery disease are presented and results are compared with those of EUROASPIRE-lll Turkey and EUROASPIRE-IV Europe.
📊
Key Findings & Data:Methods: Study was performed in 24 European countries, including Turkey (17 centers).
💡
Conclusion & Impact:Conclusion: EUROASPIRE-IV Turkey data revealed that secondary prevention was unsatisfactory and had progressed unfavorably compared with last EUROASPIRE study, some risk factors were more uncontrolled than overall European average, and coronary artery events at young age remain an important problem.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Data from EUROASPIRE-IV Turkey report investigating risk factors and adherence to guidelines in patients hospitalized for coronary artery disease are presented and results are compared with those of EUROASPIRE-lll Turkey and EUROASPIRE-IV Europe. Methods: Study was performed in 24 European countries, including Turkey (17 centers). Patients (18—80 years old) hospitalized for coronary (index) event during preceding years were identified from hospital records and interviewed 26 months later. Patient information regarding index event was acquired from hospital records. Anamnesis was obtained during the interview, and physical examination and laboratory analyses were performed. Results: Median age at the index coronary event was 58.8 years, and it was significantly decreased compared with last EUROASPIRE-lll study (60.5 years), which was conducted at the same centers years earlier (p:0.017). Of all patients, 19.3% were under 50 years of age and mean age was lower than that of EUROASPIRE-IV Europe (62.5 years). Comparing EUROASPIREIV Turkey with EUROASPIRE-III Turkey, rate of smokers increased to 25.5% from 23.1% (p:0.499), obesity increased to 40.7% from 35.5% (p:0.211), total cholesterol level increased to 49.6% from 48.3% (p:0.767), and diabetes rate increased to 39.7% from 33.6% (p:0.139), however none of the differences reached level of statistical significance. Only 11 .7% of the smokers quit after coronary event. Rates for these factors were lower in EUROASPIRE-IV Europe (16% for smoking, 37.6% for obesity, and 26.8% for diabetes). Conclusion: EUROASPIRE-IV Turkey data revealed that secondary prevention was unsatisfactory and had progressed unfavorably compared with last EUROASPIRE study, some risk factors were more uncontrolled than overall European average, and coronary artery events at young age remain an important problem.

Özet

Amaç: Koroner arter hastalığı (KAH) tanısı ile hastaneye yatırılan hastalarda risk faktörleri ve kılavuzlara uyumun araştırıldığı EUROASPIRE-IV Türkiye kolu verileri ve bulguları EUROASPIREIII Türkiye ve EUROASPIRE-IV Avrupa bulguları ile karşılaştırıldı. Yöntemler: Çalışma Türkiye'nin 17 merkez ile dahil olduğu, 24 Avrupa ülkesinde yapıldı. Son ay içinde ve yıl öncesi dönemde koroner (indeks) olay nedeniyle hastaneye yatmış 18--80 yaş arası hastalar, hastane kayıtlarından belirlenerek görüşmeye çağrıldı. Hastaların indeks olay sırasındaki bilgileri arşiv kayıtlardan elde edildi. Görüşmede detaylı öykü alınarak fiziksel muayeneleri ve laboratuvar ölçümleri yapıldı. Bulgular: Koroner olay sırasındaki yaş ortancası 58.8 yıl olup, yıl önce aynı merkezlerde yapılan EUROASPIRE-lll çalışmasına göre (60.5 yıl) anlamlı olarak düştüğü gözlendi (p:0.017). Hastaların %19.3'U 50 yaş altında olup ortalama yaş EUROASPIRE-IV Avrupa'ya (62.5 yıl) göre belirgin olarak düşük bulundu. EUROASPlRE-lll ile karşılaştırıldığında EUROASPIRE-IV Türkiye kolunda sigara içme oranı %23.1'den %25.5'e (p=0.499), obezite %35.5'ten %40.7'ye (p:0.211), total kolesterol yüksekliği °/o48.3'ten °/o49.6'ya (p:0.767) ve diyabet %33.6'dan %39.7'ye (p=0.139) yükselmiş o|- makla beraberfarklar istatistiksel açıdan anlamlı değildi. Koroner olay sonrasında sigara içicilerinin %11.7'si sigarayı bıraktı. EUROASPIREIV Avrupa'da bu risk faktörleri daha az oranda saptanmış olup sigara içme %16, obezite %376, diyabet %26.8 oranlarına idi. Sonuç: EUROASPIRE IV çalışması Türkiye kolunda koroner arter hastalarında ikincil korunmanın istenilen düzeyde olmadığı, altı yıl öncesine göre olumsuz yönde ilerlediği, genel Avrupa ortalamasına göre bazı risk faktörlerinin daha kontrolsüz olduğu ve genç yaşta koroner olayların hâlâ önemli bir sorun olduğu saptanmıştır.

🔖

Cite This Article

TOKGÖZOĞLU, L., ERGENE, O., KAYIKÇIOĞLU, M., KALKAN, A. K., BARÇIN, C., BOSTAN, C., OĞUZ, A., ÜNLÜ, S., KAYA, B., KAYMAZ, C., EMET, S., ALTAY, S., ÖZPELİT, E., ÇATAKOĞLU, A. B., ÇAKMAK, H. A., KOYLAN, N., AYDOĞDU, S., KÜLTÜRSAY, H., KAYA, C. T. (2022). EUROASPIRE-IV: European Society of Cardiology study of lifestyle, risk factors, and treatment approaches in patients with coronary artery disease: Data from Turkey. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: 2, 134–144. https://ajindex.com/articles/632313

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. World Health Organization. Cardiovascular diseases (CVDs). Available at: http://www.who.int/mediacentre/factsheets/ fs317/en/
  2. Van Camp G. Cardiovascular disease prevention. Acta Clin Belg 2014;69:407–11
  3. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581–3
  4. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929–40
  5. Tokgözoğlu L, Kaya EB, Erol C, Ergene O. EUROASPIRE III: a comparison between Turkey and Europe. Turk Kardiyol Dern Ars 2010;38:164–72
  6. Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636–48
  7. De Backer G, Besseling J, Chapman J, Hovingh GK, Kastelein JJ, Kotseva K, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 2015;241:169–75
  8. Gielen S, Landmesser U. The Year in Cardiology 2013: cardiovascular disease prevention. Eur Heart J 2014;35:307–12
  9. Havanı koru. Dumansız hava sahası. Erişim:
  10. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169–80
  11. Tokgözoğlu L, Özdemir R, Altındağ R, Ceyhan C, Yeter E, Öztürk C, et al. Patient characteristics and statin discontinuation-related factors during treatment of hypercholesterolemia: an observational non-interventional study in patients with statin discontinuation (STAY study). Turk Kardiyol Dern Ars 2016;44:53–64
  12. Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey. Atherosclerosis 2016;246:243–50
  13. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I.